Growth Hormone (Somatropin) vs Testosterone Enanthate

Mechanism

Recombinant human growth hormone (rhGH/somatropin) is a 191-amino acid protein identical to endogenous GH. It binds the GH receptor (GHR), a type I cytokine receptor, activating the JAK2-STAT5 signaling cascade that drives hepatic IGF-1 production — the primary mediator of GH's anabolic effects. GH directly stimulates lipolysis via hormone-sensitive lipase (HSL) activation and inhibits lipogenesis. It promotes chondrocyte proliferation, collagen synthesis, and linear bone growth. GH also enhances protein synthesis through mTOR pathway activation and improves nitrogen balance. Pulsatile secretion patterns are important — continuous GH exposure preferentially drives IGF-1, while pulsatile release favors direct lipolytic effects.

Standard Dosing

Research indicates 1-2 IU/day (0.33-0.67 mg/day) subcutaneously for anti-aging and body composition. Clinical GHD replacement: 0.2-0.6 mg/day titrated to IGF-1 levels.

Timing

Inject subcutaneously in the morning fasted (mimics physiological pulse) or before bed (mimics nocturnal secretion). Rotate injection sites (abdomen, thigh, deltoid). If using with insulin, separate GH injection by several hours. Fasted-state injection preferred for maximal lipolytic effect.

Cycle Duration

Long-term (6-12+ months) for body composition benefits. Clinical GHD replacement is indefinite. Minimum 3-6 months to assess efficacy.

Side Effects

• Fluid retention and edema (dose-dependent, typically resolves in 2-4 weeks)
• Carpal tunnel syndrome and joint pain
• Insulin resistance and elevated fasting glucose
• Headache
• Numbness and paresthesias
• Potential increased cancer risk with chronic supraphysiological IGF-1 levels
• Gynecomastia
• Acromegalic features with long-term excessive dosing (jaw growth, digit enlargement)

Contraindications

• Active malignancy (GH/IGF-1 promotes cell proliferation)
• Active proliferative or preproliferative diabetic retinopathy
• Acute critical illness (GH increased mortality in ICU patients)
• Active intracranial lesion or tumor
• Prader-Willi syndrome with severe obesity or respiratory impairment
• Closed epiphyses (for linear growth indication only)

Best Stacking Partners

Mechanism

Testosterone enanthate is a long-acting esterified testosterone prodrug with a heptanoic acid ester at the 17-beta hydroxyl group, extending its half-life to approximately 4.5-5 days. Upon hydrolysis by tissue esterases, free testosterone activates nuclear androgen receptors, upregulating anabolic gene transcription including myostatin suppression and IGF-1 induction. It also modulates the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback on GnRH and LH secretion.

Standard Dosing

Research indicates 100-200 mg administered via intramuscular or subcutaneous injection every 7-14 days for testosterone replacement.

Timing

Consistent injection schedule. Twice-weekly splits provide more stable blood levels due to the slightly shorter half-life compared to cypionate.

Cycle Duration

Ongoing for TRT. Suppression of endogenous production is expected within weeks of initiation.

Side Effects

• Polycythemia / elevated hematocrit
• Acne and oily skin
• Testicular atrophy (without hCG)
• Gynecomastia
• Mood fluctuations
• Fluid retention
• Hair thinning (androgen-sensitive individuals)

Contraindications

• Prostate cancer or elevated PSA without urological clearance
• Male breast cancer
• Polycythemia (hematocrit >54%)
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Pregnancy or potential pregnancy exposure

Best Stacking Partners